EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
... Belgium-based TiGenix raised $36 million on the sale of 2.3 million ADSs at a 14% discount to the converted price of the Euronext-listed shares. Its first day drop of 24.5% was the worst first-day performance of the year.